Artivion Inc (AORT) Stock Price, Quote & News

Company Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THOR...

Industry: Medical Devices

Sector: Healthcare

Phone: 770 419 3355

Website: artivion.com

Address:

1655 Roberts Boulevard NW, Kennesaw, United States

Albino_Trader123 Aug. 22 at 6:18 PM

$AORT Very clean chart. nice fundamentals and picture perfect breakout and nobody watching

0 · Reply

JarvisFlow Aug. 22 at 11:30 AM

Needham has updated their rating for Artivion ( $AORT ) to Buy with a price target of 50.

0 · Reply

stockanalysis_ Aug. 19 at 10:36 PM

After Hours Losers: $MEDP $AORT $LZB $JHX $GTLS Save this screener here: https://stockanalysis.com/markets/afterhours/losers/ Discount code SAVEONTRADING to pick up Stock Analysis for just $5.91/m.

1 · Reply

JarvisFlow Aug. 13 at 3:17 PM

Ladenburg Thalmann has updated their rating for Artivion ( $AORT ) to Neutral with a price target of 38.8.

0 · Reply

souldout Aug. 11 at 11:32 AM

$ATR AMS Advanced Medical Solutions on LSE sounds like buyout on way according to Betaville $AORT $ZBH https://www.betaville.co.uk/betaville-intelligence/8el8u1xa2w960e6jtj9hmghf9czy1cwlu45j

0 · Reply

Doozio Aug. 8 at 6:24 PM

Yo $AORT a say it was always during 🐒🍌🧠⏰♾️

0 · Reply

Knot2 Aug. 8 at 5:44 PM

$AORT hedges shorted the launch

0 · Reply

howardlindzon Aug. 8 at 4:16 PM

$AORT another breakout In medical devices...only 2 b. no followers ...watching. no position

2 · Reply

JarvisFlow Aug. 8 at 1:43 PM

Stifel has updated their rating for Artivion ( $AORT ) to Buy with a price target of 40.

0 · Reply

JarvisFlow Aug. 8 at 12:00 PM

Needham updates rating for Artivion ( $AORT ) to Buy, target set at 32 → 45.

0 · Reply

Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 15 days ago

Artivion Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:10 PM EDT - 23 days ago

Artivion to Participate in Upcoming Investor Conferences

Jul 24, 2025, 4:10 PM EDT - 4 weeks ago

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results

May 28, 2025, 5:51 PM EDT - 3 months ago

Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

May 14, 2025, 4:01 PM EDT - 3 months ago

Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

May 5, 2025, 10:37 PM EDT - 3 months ago

Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:05 PM EDT - 3 months ago

Artivion Reports First Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 3 months ago

Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

Apr 21, 2025, 4:10 PM EDT - 4 months ago

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results

Mar 4, 2025, 4:05 PM EST - 6 months ago

Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Feb 24, 2025, 11:00 PM EST - 6 months ago

Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 6 months ago

Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 10, 2025, 4:10 PM EST - 6 months ago

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results

Jan 27, 2025, 8:00 AM EST - 7 months ago

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting

Dec 9, 2024, 10:52 AM EST - 9 months ago

US medical device giant Artivion says hackers stole files during cybersecurity incident

Dec 9, 2024, 8:00 AM EST - 9 months ago

Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

Nov 9, 2024, 12:02 PM EST - 10 months ago

Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 10 months ago

Artivion Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 4:15 PM EDT - 10 months ago

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

Oct 10, 2024, 4:10 PM EDT - 11 months ago

Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Aug 10, 2024, 2:45 PM EDT - 1 year ago

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Artivion Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 4:10 PM EDT - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Artivion Amends Agreements with Endospan

Jun 21, 2024, 5:01 PM EDT - 1 year ago

Data-Driven Growth Fuels More Upside For Overlooked Artivion

May 6, 2024, 10:47 PM EDT - 1 year ago

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:05 PM EDT - 1 year ago

Artivion Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:05 AM EDT - 1 year ago

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

Apr 22, 2024, 4:10 PM EDT - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

Apr 1, 2024, 4:10 PM EDT - 1 year ago

Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 4:10 PM EST - 1 year ago

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Feb 15, 2024, 8:22 PM EST - 1 year ago

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 4:05 PM EST - 1 year ago

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 1, 2024, 4:10 PM EST - 1 year ago

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

Jan 29, 2024, 8:25 AM EST - 1 year ago

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

Jan 18, 2024, 4:05 PM EST - 1 year ago

Artivion Obtains $350 Million in Senior Secured Credit Facilities

ARES

Dec 6, 2023, 4:15 PM EST - 1 year ago

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.

Nov 9, 2023, 8:25 AM EST - 1 year ago

Artivion Announces Completion of Enrollment in PERSEVERE Trial

Nov 5, 2023, 1:51 AM EDT - 1 year ago

Artivion, Inc. (AORT) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Artivion Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:10 PM EDT - 2 years ago

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results

Oct 13, 2023, 2:37 PM EDT - 2 years ago

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 5, 2023, 4:15 PM EDT - 2 years ago

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

Oct 5, 2023, 4:05 PM EDT - 2 years ago

Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

Sep 26, 2023, 8:25 AM EDT - 2 years ago

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

Sep 14, 2023, 8:05 AM EDT - 2 years ago

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

Aug 5, 2023, 1:28 PM EDT - 2 years ago

Artivion, Inc. (AORT) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Artivion Reports Second Quarter 2023 Financial Results

Albino_Trader123 Aug. 22 at 6:18 PM

$AORT Very clean chart. nice fundamentals and picture perfect breakout and nobody watching

0 · Reply

JarvisFlow Aug. 22 at 11:30 AM

Needham has updated their rating for Artivion ( $AORT ) to Buy with a price target of 50.

0 · Reply

stockanalysis_ Aug. 19 at 10:36 PM

After Hours Losers: $MEDP $AORT $LZB $JHX $GTLS Save this screener here: https://stockanalysis.com/markets/afterhours/losers/ Discount code SAVEONTRADING to pick up Stock Analysis for just $5.91/m.

1 · Reply

JarvisFlow Aug. 13 at 3:17 PM

Ladenburg Thalmann has updated their rating for Artivion ( $AORT ) to Neutral with a price target of 38.8.

0 · Reply

souldout Aug. 11 at 11:32 AM

$ATR AMS Advanced Medical Solutions on LSE sounds like buyout on way according to Betaville $AORT $ZBH https://www.betaville.co.uk/betaville-intelligence/8el8u1xa2w960e6jtj9hmghf9czy1cwlu45j

0 · Reply

Doozio Aug. 8 at 6:24 PM

Yo $AORT a say it was always during 🐒🍌🧠⏰♾️

0 · Reply

Knot2 Aug. 8 at 5:44 PM

$AORT hedges shorted the launch

0 · Reply

howardlindzon Aug. 8 at 4:16 PM

$AORT another breakout In medical devices...only 2 b. no followers ...watching. no position

2 · Reply

JarvisFlow Aug. 8 at 1:43 PM

Stifel has updated their rating for Artivion ( $AORT ) to Buy with a price target of 40.

0 · Reply

JarvisFlow Aug. 8 at 12:00 PM

Needham updates rating for Artivion ( $AORT ) to Buy, target set at 32 → 45.

0 · Reply

BigSqueezeComing Aug. 8 at 10:34 AM

$AORT hot gappers.

0 · Reply

Estimize Aug. 7 at 3:00 PM

$AORT reports after the close, Estimize Consensus +0.01 EPS and -0.46M Revs compared to WS http://www.estimize.com/aort/fq2-2025?utm_conten

0 · Reply

JarvisFlow Jun. 17 at 11:30 AM

Canaccord Genuity updates rating for Artivion ( $AORT ) to Buy, target set at 35.

0 · Reply

Estimize May. 8 at 3:13 PM

Wall St is expecting 0.12 EPS for $AORT Q2 [Reporting 07/31 AMC] http://www.estimize.com/intro/aort?chart=historical&metric_name=eps&utm_co

0 · Reply

Wigglyick May. 7 at 4:08 PM

$AORT hidden gem ? Only 300 watchers on ST. Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Pop on ER, increasing sales.

1 · Reply

PenkeTrading May. 7 at 3:16 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Artivion Inc. Is that bullish or bearish? $AORT #Artivion #RsiOverbought #NYSE

0 · Reply

MaverikIT May. 6 at 4:16 PM

$PONY $WRD $SEDG $XPEL $AORT

0 · Reply

MaverikIT May. 6 at 3:11 PM

$AORT +2.32 - raising FY25 sale$

0 · Reply

JarvisFlow May. 6 at 11:00 AM

Needham updates rating for Artivion ( $AORT ) to Buy, target set at 32.

0 · Reply

Estimize May. 6 at 12:27 AM

$AORT reported 0.06 EPS and 98.98 revenue for Q1. http://www.estimize.com/intro/aort?chart=historical&metric_name=eps&utm_content=AORT&utm_

0 · Reply

Rage_Against_The_Machine May. 5 at 11:06 AM

$AORT's NEXUS TRIOMPHE trial shows a 63% reduction in major adverse events at 30 days - a critical milestone for their aortic arch device. With PMA submission planned after 1-year data, this could be the catalyst they need. CEO Mackin's optimism suggests confidence in long-term outcomes. High-risk patients getting safer options = market expansion. https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-new-clinical-data-from-nexus-triomphe-ide-trial-at-the-105th-american-association-for-thoracic-surgery-aats-annual-meeting-302445689.html

0 · Reply

swingingtech Apr. 24 at 2:21 PM

$IJR $TRUP $BFS $AORT https://wallstreetwaves.com/analysts-predict-34-growth-potential-for-ijr/

1 · Reply

Market Cap	2.04B
Revenue (ttm)	388.54M
Net Income (ttm)	-13.36M
EPS (ttm)	N/A
PE Ratio	102.43
Forward PE	79.67
Profit Margin	-3.44%
Debt to Equity Ratio	0.51

Volume	661,000
Avg Vol	438,836
Day's Range	N/A - N/A
Shares Out	47.18M
Stochastic %K	93%
Beta	1.64
Analysts	Strong Sell
Price Target	$40.26